PH12020550726B1 - Method and compositions for the treatment of diabetes and related symptoms - Google Patents

Method and compositions for the treatment of diabetes and related symptoms

Info

Publication number
PH12020550726B1
PH12020550726B1 PH1/2020/550726A PH12020550726A PH12020550726B1 PH 12020550726 B1 PH12020550726 B1 PH 12020550726B1 PH 12020550726 A PH12020550726 A PH 12020550726A PH 12020550726 B1 PH12020550726 B1 PH 12020550726B1
Authority
PH
Philippines
Prior art keywords
diabetes
compositions
treatment
related symptoms
glutamine
Prior art date
Application number
PH1/2020/550726A
Other languages
English (en)
Other versions
PH12020550726A1 (en
Inventor
Yutaka Niihara
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12020550726(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Publication of PH12020550726A1 publication Critical patent/PH12020550726A1/en
Publication of PH12020550726B1 publication Critical patent/PH12020550726B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PH1/2020/550726A 2011-11-21 2012-11-17 Method and compositions for the treatment of diabetes and related symptoms PH12020550726B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
PCT/US2012/000557 WO2013077893A1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Publications (2)

Publication Number Publication Date
PH12020550726A1 PH12020550726A1 (en) 2021-06-14
PH12020550726B1 true PH12020550726B1 (en) 2022-11-09

Family

ID=48470183

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2020/550726A PH12020550726B1 (en) 2011-11-21 2012-11-17 Method and compositions for the treatment of diabetes and related symptoms
PH1/2014/501052A PH12014501052B1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH1/2014/501052A PH12014501052B1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Country Status (10)

Country Link
US (2) US20130143968A1 (https=)
EP (2) EP3437649A1 (https=)
JP (4) JP6089042B2 (https=)
CN (3) CN108478551A (https=)
BR (1) BR112014011898A2 (https=)
ES (1) ES2785094T3 (https=)
HK (1) HK1257401A1 (https=)
IN (1) IN2014KN01037A (https=)
PH (2) PH12020550726B1 (https=)
WO (1) WO2013077893A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
IL296055A (en) 2017-08-14 2022-10-01 Axcella Health Inc Amino acid compositions for the treatment of liver disease
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
CA2418543A1 (en) * 2001-06-27 2003-01-09 Probiodrug Ag New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CA2774197A1 (en) * 2006-04-22 2008-04-03 Harbor Biosciences, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
EP2077110A4 (en) * 2006-09-29 2012-06-27 Ajinomoto Kk GLUTAMINE-CONTAINING COMPOSITION FOR INCREASING BLOOD FLOW
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
RS56054B1 (sr) * 2009-01-12 2017-09-29 Biokier Inc Smeša i metod za lečenje dijabetesa
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
CN102711800A (zh) 2009-09-23 2012-10-03 拜奥基尔公司 治疗糖尿病的组合物和方法

Also Published As

Publication number Publication date
EP2782588B1 (en) 2020-04-15
BR112014011898A2 (pt) 2017-05-16
US20130143968A1 (en) 2013-06-06
ES2785094T3 (es) 2020-10-05
HK1257401A1 (zh) 2019-10-18
EP2782588A4 (en) 2015-05-20
PH12014501052A1 (en) 2014-06-30
EP3437649A1 (en) 2019-02-06
US20190192463A1 (en) 2019-06-27
IN2014KN01037A (en) 2015-10-09
CN108354916A (zh) 2018-08-03
CN103945858A (zh) 2014-07-23
JP2014533689A (ja) 2014-12-15
JP6089042B2 (ja) 2017-03-01
WO2013077893A1 (en) 2013-05-30
JP6389495B2 (ja) 2018-09-12
CN108478551A (zh) 2018-09-04
EP2782588A1 (en) 2014-10-01
JP6550160B2 (ja) 2019-07-24
JP2018199692A (ja) 2018-12-20
JP2017052766A (ja) 2017-03-16
PH12020550726A1 (en) 2021-06-14
JP2018115175A (ja) 2018-07-26
PH12014501052B1 (en) 2020-10-09

Similar Documents

Publication Publication Date Title
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
WO2010080756A3 (en) Harmine derivatives for reducing body weight
PH12015501108A1 (en) Treatment of pulmonary disease
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MY173877A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
PH12015501291B1 (en) Functionalized exendin-4 derivatives
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
EA201690327A1 (ru) Терапевтические способы
IN2014KN01255A (en) Methods and compositions for the treatment of diverticulosis
PH12014501052B1 (en) Methods and compositions for the treatment of diabetes and related symptoms
NZ707773A (en) Methods of treating liver diseases
UA113859C2 (xx) Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем
PH12014500577A1 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
PH12012501476A1 (en) Aminoquinoline derivatives
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
IN2014MN02382A (https=)
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors